H

Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627

Watchlist Manager
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Watchlist
Price: 4.99 CNY 4.61% Market Closed
Market Cap: 24.7B CNY
Have any thoughts about
Hubei Biocause Pharmaceutical Co Ltd?
Write Note

Hubei Biocause Pharmaceutical Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hubei Biocause Pharmaceutical Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Pre-Tax Income
-ÂĄ1.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
China Life Insurance Co Ltd
SSE:601628
Pre-Tax Income
ÂĄ129.6B
CAGR 3-Years
14%
CAGR 5-Years
21%
CAGR 10-Years
14%
Ping An Insurance Group Co of China Ltd
SSE:601318
Pre-Tax Income
ÂĄ159.2B
CAGR 3-Years
-1%
CAGR 5-Years
-5%
CAGR 10-Years
11%
New China Life Insurance Company Ltd
SSE:601336
Pre-Tax Income
ÂĄ20.1B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
10%
S
Sunshine Insurance Group Co Ltd
HKEX:6963
Pre-Tax Income
ÂĄ5.8B
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hubei Biocause Pharmaceutical Co Ltd
Glance View

Market Cap
24.7B CNY
Industry
Insurance

Hubei Biocause Pharmaceutical Co., Ltd began its journey in the health sector by positioning itself strategically in the pharmaceutical industry. With its headquarters set in the Hubei Province of China, this company has intricately woven itself into the fabric of modern healthcare. Primarily, it thrives by developing, manufacturing, and distributing a variety of pharmaceutical products including both traditional and modern-medicine drugs. The journey of Biocause is punctuated by its research-driven approach, which focuses on innovation and quality control across its production lines, ensuring it stays at the forefront of pharmaceutical advancements. Revenue generation for Hubei Biocause predominantly comes from the sale of medications and healthcare products, but the company's financial tapestry is more diversified. It has explored opportunities by extending its business horizon beyond pharmaceuticals, tapping into other ventures such as insurance services. This diversification has enabled Biocause to stabilize its financial structure and mitigate risk, leveraging its steady pharma income to branch into realms that complement its healthcare base. Alongside, their strategic partnerships and alliances further bolster their market position, allowing for a broadened geographical reach and a more substantial impact on the sectors they operate within. Thus, Hubei Biocause crafts a story not only of pharmaceutical excellence but of strategic breadth that spawns wider market opportunities.

Intrinsic Value
4.61 CNY
Overvaluation 8%
Intrinsic Value
Price
H

See Also

What is Hubei Biocause Pharmaceutical Co Ltd's Pre-Tax Income?
Pre-Tax Income
-1.7B CNY

Based on the financial report for Sep 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's Pre-Tax Income amounts to -1.7B CNY.

What is Hubei Biocause Pharmaceutical Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 1Y
-91%

Over the last year, the Pre-Tax Income growth was -91%.

Back to Top